Form 4: CareDx Director Sells Over 10,000 Shares Under Pre-Arranged Trading Plan

Hannah Valantine, a Director at CareDx, Inc., sold 10,570 shares of common stock for approximately $202,500 through a pre-scheduled Rule 10b5-1 trading plan.

Summary

• Hannah Valantine, a Director of CareDx, Inc. (CDNA), reported the sale of 10,570 shares of the company's common stock.
• The transaction occurred on June 18, 2025, at a weighted average price of $19.1642 per share.
• The total value of the shares sold amounts to approximately $202,500.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Ms. Valantine on December 12, 2024.
• Following this transaction, Ms. Valantine beneficially owns 38,994 shares of CareDx common stock.
• The shares were sold in multiple transactions within a price range of $19.00 to $19.62, inclusive.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can sometimes be viewed negatively, the execution under a Rule 10b5-1 plan significantly mitigates any negative inference, suggesting a pre-planned financial decision rather than a reaction to new, negative company information.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate, non-public information, which mitigates concerns about opportunistic insider selling.

Negatives

• A director's sale of shares, even under a pre-arranged plan, reduces their direct equity stake in the company, which some investors might interpret as a slight reduction in alignment with shareholder interests, though often for personal financial planning reasons.

Risks

• No specific risks to the company's operations or financial health are mentioned in this Form 4 filing, which is solely focused on an insider transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The sale by a director slightly reduces insider ownership, which could be perceived as a minor decrease in alignment, though the 10b5-1 plan context lessens this concern.

Key Dates

Keywords

CareDx, CDNA, Form 4, Insider Trading, Stock Sale, Director, Rule 10b5-1, Equity Transaction, Beneficial Ownership